Increased Resistance of SARS-CoV-2 Variant P.1 (Brazil) to Antibody Neutralization

  

View ORCID ProfilePengfei Wang, Maple Wang, Jian Yu, Gabriele Cerutti, Manoj S. Nair, Yaoxing Huang, Peter D. Kwong, Lawrence Shapiro,  View ORCID ProfileDavid D. Ho

doi: https://doi.org/10.1101/2021.03.01.433466

This article is a preprint and has not been certified by peer review [what does this mean?].

PDF: https://www.biorxiv.org/content/10.1101/2021.03.01.433466v1.full.pdf

Abstract

The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to antibody neutralization has been described recently. We now report that another emergent variant from Brazil, P.1, is not only refractory to multiple neutralizing monoclonal antibodies, but also more resistant to neutralization by convalescent plasma (6.5 fold) and vaccinee sera (2.2-2.8 fold). The P.1 variant threatens current antibody therapies but less so the protective efficacy of our vaccines.

Competing Interest Statement

P.W., J.Y., M.N., Y.H., and D.D.H. are inventors on a provisional patent application on mAbs to SARS-CoV-2.

https://www.biorxiv.org/content/10.1101/2021.03.01.433466v1